Company news

Onco-innovations Ltd. (NEO:ONCO) news

Onco-innovations Ltd. news releases on 6ix. Latest, Sep 24, 2026: SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments…

Onco-innovations Ltd. (NEO:ONCO) news

Press releases & updates

SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO)

CORRECTED: Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition

Onco-Innovations Provides Interim Report on Microsome Studies Across Three Species

Onco-Innovations Announces Shares for Debt Settlement

Onconetix Acquisition Target Realbotix Launches Pilot with Leading European Telecommunications Company to Deploy Humanoid Robots in Live Presentations and Events

Onco-Innovations Enters into LOI with Ifowonco for Exclusive Option and Worldwide Licence to LAG-3 Small-Molecule Inhibitor Program

Realbotix Reports Financial Results for Q3-2026

Onconetix Acquisition Target Realbotix Secures Agreement for Humanoid Robot Appearance on Emmy Award-Winning Streaming Series

Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG

Realbotix Corp. Provides Corporate Structure and Operations Update

Onco-Innovations Initiates ADME Studies Supporting Development of ONC010

Onco-Innovations Announces Entry into Loan Agreements

Onco-Innovations Completes Analytical Reference Standard Preparation Program for ONC010’s API

Onconetix Highlights Realbotix Partnership with Bloom Services to Launch UK Pilot Using Humanoid Robots to Combat Elderly Social Isolation

Onco-Innovations Announces Term Sheet for Notional CAD$5 Million Performance-Based Funding Arrangement and Amendments to Previously Announced Financing

Onco-Innovations Initiates Polymer Process Development and Characterization Program for ONC010

NetworkNewsAudio Announces Audio Press Release (APR) Discussing the Development of PNKP Inhibitors in Oncology Drug Development

Onconetix Highlights Realbotix's Launch of Humanoid Robot and AI Teachers Assistant Pilot Program in New York State School District

Onco-Innovations Engages Nanosoft Polymers to Advance Polymer and Drug Delivery Development for ONC010

Onco-Innovations Announces Non-Brokered LIFE Offering

Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development

Onco-Innovations Completes Project with Kuano, Using Their Quantum-Based Platform to Deliver Insights for PNKP Inhibitor Technology Optimization

Onco-Innovations Announces Initiation of API Process Development and Intermediate Scale-Up Program for its Proprietary PNKP Inhibitor Technology

Onco-Innovations Signs LOI with Nanosoft Polymers to Advance Polymer and Drug Delivery Development for the ONC010 Program

Onco-Innovations Advances 1kg Scale-Up of B4 Precursor Supporting ONC010 Manufacturing and Clinical Development Program

Realbotix Reports Financial Results for Q2-2026

Onconetix, Inc. Announces 1-for-10 Reverse Stock Split

Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate

Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation Study

Onco-Innovations Announces Initiation of Research Collaboration within PROmAI

Onco-Innovations Announces Inka Health Collaborative Research to Advance Oncology Evidence Generation

Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies

Onco-Innovations Announces Successful Scale-Up of Key Materials Used in the Synthesis of its Active Pharmaceutical Ingredient for its PNKP Inhibitor Technology Program

Onco-Innovations Advances Polymer Testing as It Moves Its PNKP Inhibitor Technology Toward IND-Enabling Studies

Onco-Innovations Announces Completion of Analytical Method Development for Monomer Intermediate 1 Supporting ONC010 Program

Onco-Innovations Strengthens Executive Leadership with Appointment of Dr. Islam Mohamed as Chief Medical Officer and Stephen M. Novak as Chief of Research and Development

Onconetix Highlights Realbotix's Launch of Vinci AI Vision System with Delivery of First Vinci-Equipped Humanoid Robot to Ericsson

Onco-Innovations Executes Engagement Agreement with RDI Partners and Establishes Onco-Innovations AU Pty. Ltd. to Advance Australian Phase I Strategy

Onconetix Highlights Realbotix AI Humanoid Robot Delivery Update

OneMedNet, Onco-Innovations and Inka Health Announces Collaboration Aimed to Accelerate Potential for Oncology Drug Development Using Real-World Data and AI

Onconetix Appoints David White as Chief Executive Officer and Sammy Dorf as Member of the Board of Directors

Onconetix Highlights Realbotix's Role in Ericsson's World-First 6G Trial Demonstration

Onconetix, Inc. Announces 1-for-5 Reverse Stock Split

Onco-Innovations Announces Closing of Private Placement

Realbotix Corp. Announces the Sale of Realbotix, LLC Subsidiary to a NASDAQ Listed Issuer

Onconetix to Acquire Realbotix LLC, USA-based, AI-Powered Humanoid Robotics Company

Onco-Innovations Announces Filing of Preliminary Base Shelf Prospectus

Onco-Innovations Announces Private Placement

Onco-Innovations Engages i2i Marketing Group Engagement for Market Awareness Services

Onco-Innovations Chairs Colorectal Cancer Canada Precision Oncology Forum Generating Roadmaps for the Next Era of Cancer Care